The UB team that a decade ago helped usher in a new era in acute stroke treatment has turned its innovative approach to addressing the rare but potentially deadly phenomena when multiple blood clots strike deep in the veins of the brain.
A story in The Buffalo News describes how the collaborative environment at UB’s Clinical and Translational Research Center fuels research between UB researchers and directly impacts the clinical work that happens downstairs at the Gates Vascular Institute.
Buffalo Business First featured Ciprion Ionita, assistant professor of biomedical engineering and neurosurgery, and his startup, QAS.AI, which has risen quickly from UB labs into a project approaching human trials.
Technology.org reported on a company founded by Ciprian Ionita that is looking at how artificial intelligence (AI) could improve treatment for certain type of aneurysms.